Abbie S. Ireland

Abbie S. Ireland

Auto-generated profile, based on publicly available information

Abbie S. Ireland

Department of Pharmacology and Cancer Biology, Duke University, Durham, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 September 2025 in Nature
Verified
Journal Article
Open access
PDF file
AIAbbie S. Ireland
Abbie S. Ireland
DXDaniel A. Xie
Daniel A. Xie
SHSarah B. Hawgood
Sarah B. Hawgood
MBMargaret W. Barbier
Margaret W. Barbier
LZLisa Y. Zuo
Lisa Y. Zuo
TOTrudy G. Oliver
Trudy G. Oliver
Neuroendocrine and tuft cells are rare chemosensory epithelial lineages defined by the expression of ASCL1 and POU2F3 transcription factors, respectively. Neuroendocrine cancers, including small cell lung cancer (SCLC), frequently display tuft-like subsets, a feature linked to poor patient outcomes1,2,3,4,5,6,7,8,9. The mechanisms driving neuroendocrine–tuft tumour heterogeneity and the origins of tuft-like cancers are unknown. Using multiple genetically engineered animal models of SCLC, we demonstrate that a basal cell of origin (but not the accepted neuroendocrine origin) generates neuroendocrine–tuft-like tumours that highly recapitulate human SCLC. Single-cell clonal analyses of basal-derived SCLC further uncovered unexpected transcriptional states, including an Atoh1+ state, and lineage trajectories underlying neuroendocrine–tuft plasticity. Uniquely in basal cells, the introduction of genetic alterations enriched in human tuft-like SCLC, including high MYC, PTEN loss and ASCL1 suppression, cooperates to promote tuft-like tumours. Transcriptomics of 944 human SCLCs revealed a basal-like subset and a tuft–ionocyte-like state that altogether demonstrate notable conservation between cancer states and normal basal cell injury response mechanisms10,11,12,13. Together, these data indicate that the basal cell is a probable origin for SCLC and other neuroendocrine–tuft cancers that can explain neuroendocrine–tuft heterogeneity, offering new insights for targeting lineage plasticity.

15 November 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
AIAbbie S. Ireland
Abbie S. Ireland
SHSarah B. Hawgood
Sarah B. Hawgood
DXDaniel A. Xie
Daniel A. Xie
MBMargaret W. Barbier
Margaret W. Barbier
SLScarlett Lucas-Randolph
Scarlett Lucas-Randolph
TOTrudy G. Oliver
Trudy G. Oliver
Summary paragraph: Neuroendocrine and tuft cells are rare, chemosensory epithelial lineages defined by expression of ASCL1 and POU2F3 transcription factors, respectively 1,2 . Neuroendocrine cancers, including small cell lung cancer (SCLC), frequently display tuft-like subsets, a feature linked to poor patient outcomes 3–13 . The mechanisms driving neuroendocrine–tuft tumour heterogeneity, and the origins of tuft-like cancers are unknown. Using multiple genetically-engineered animal models of SCLC, we demonstrate that a basal cell of origin (but not the accepted neuroendocrine origin) generates neuroendocrine–tuft-like tumours that highly recapitulate human SCLC. Single-cell clonal analyses of basal-derived SCLC further uncovers unexpected transcriptional states and lineage trajectories underlying neuroendocrine–tuft plasticity. Uniquely in basal cells, introduction of genetic alterations enriched in human tuft-like SCLC, including high MYC, PTEN loss, and ASCL1 suppression, cooperate to promote tuft-like tumours. Transcriptomics of 944 human SCLCs reveal a basal-like subset and a tuft-ionocyte-like state that altogether demonstrate remarkable conservation between cancer states and normal basal cell injury response mechanisms 14–18 . Together, these data suggest that the basal cell is a plausible origin for SCLC and other neuroendocrine-tuft cancers that can explain neuroendocrine–tuft heterogeneity—offering new insights for targeting lineage plasticity.

10 March 2025 in Molecular Cancer Research
Verified
Journal Article
Closed access
Dianna HuismanDianna Huisman
Dianna Huisman
DCDeepan Chatterjee
Deepan Chatterjee
RSRobert A. Svoboda
Robert A. Svoboda
HVHeidi M. Vieira
Heidi M. Vieira
AIAbbie S. Ireland
Abbie S. Ireland
RLRobert E. Lewis
Robert E. Lewis
Small cell lung carcinoma (SCLC) tumors are heterogeneous, with a subpopulation of cells primed for tumor initiation. In this study, we show that kinase suppressor of Ras 2 (KSR2) promotes the self-renewal and clonogenicity of SCLC cells. KSR2 is a molecular scaffold that promotes Raf/MEK/ERK signaling. KSR2 is preferentially expressed in the ASCL1 subtype of SCLC (SCLC-A) tumors and is expressed in pulmonary neuroendocrine cells, one of the identified cells of origin for SCLC-A tumors. The expression of KSR2 in SCLC and pulmonary neuroendocrine cells was previously unrecognized and serves as a novel model for understanding the role of KSR2-dependent signaling in normal and malignant tissues. Disruption of KSR2 in SCLC-A cell lines inhibits the colony-forming ability of tumor-propagating cells in vitro and their tumor-initiating capacity in vivo. The effect of KSR2 depletion on self-renewal and clonogenicity is dependent on the interaction of KSR2 with ERK. These data indicate that the expression of KSR2 is an essential driver of SCLC-A tumor–propagating cell function and therefore may play a role in SCLC tumor initiation. These findings shed light on a novel effector promoting initiation of SCLC-A tumors and a potential subtype-specific therapeutic target. Implications: Manipulation of the molecular scaffold KSR2 in SCLC-A cells reveals its contribution to self-renewal, clonogenicity, and tumor initiation.

18 June 2026 in Cancer Research
Verified
Journal Article
Open access
LILuke T. Izzo
Luke T. Izzo
TRTony Reyes
Tony Reyes
SMSrijan Meesala
Srijan Meesala
AIAbbie S. Ireland
Abbie S. Ireland
LELisa B. Earnest-Noble
Lisa B. Earnest-Noble
TOTrudy G. Oliver
Trudy G. Oliver
Lung squamous cell carcinoma (LUSC) is a basal-like subtype of lung cancer with limited treatment options. While prior studies have identified tumor-propagating cell states in squamous tumors, further work is needed to elucidate the broader landscape of intra-tumoral heterogeneity within LUSC. Here, we employed SOX2-driven mouse models, organoid cultures, and single-cell transcriptomic analyses to uncover cell fate diversity within LUSC, identifying a KRT13+ hillock-like population of slower-dividing tumor cells characterized by immunomodulatory gene expression signatures. The tumor hillock-like state was conserved across multiple animal and human-derived models and was computationally predicted in the majority of human LUSCs as well as head and neck and esophageal squamous tumors. Analysis of the cellular origins of tumor hillock-like states indicated that lung club cells give rise to tumors with luminal hillock-like populations while basal-like tumor-propagating cells transition into basal hillock-like states, resembling lineage plasticity trajectories of the normal lung. Mechanistically, KLF4 promoted the KRT13+ hillock-like state and contributed to resistance to oxidative stress and platinum-based chemotherapy in vitro. Together, these results provide molecular insights into the lineage plasticity underlying intratumoral heterogeneity within LUSC, offering potential avenues for developing therapeutic strategies.

15 September 2026
Verified
Other
Open access
PDF file
LILuke T. Izzo
Luke T. Izzo
TRTony Reyes
Tony Reyes
SMSrijan Meesala
Srijan Meesala
AIAbbie S. Ireland
Abbie S. Ireland
LELisa B. Earnest-Noble
Lisa B. Earnest-Noble
TOTrudy G. Oliver
Trudy G. Oliver
NGFR + tumor cells sorted from SNL tumors for scRNA-seq, related to Fig. 2.

15 September 2026
Verified
Other
Open access
LILuke T. Izzo
Luke T. Izzo
TRTony Reyes
Tony Reyes
SMSrijan Meesala
Srijan Meesala
AIAbbie S. Ireland
Abbie S. Ireland
LELisa B. Earnest-Noble
Lisa B. Earnest-Noble
TOTrudy G. Oliver
Trudy G. Oliver
SEACR peaks annotated using HOMER from KLF4 Cut&Run in SNL tumor organoids, related to Fig. 7